Arecor Therapeutics - Collaboration with global pharmaceutical partner

Arecor Therapeutics

26/03/2025 07:00

RNS Number : 1482C

Arecor Therapeutics PLC

26 March 2025

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

ARECOR ENTERS COLLABORATION WITH MAJOR GLOBAL PHARMACEUTICAL PARTNER

 

-      Collaboration will leverage ArestatTM to develop a novel formulation of partner's proprietary product with enhanced properties

-      Work will be fully funded by partner

 

Cambridge, UK, 26 March 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has signed a formulation study agreement with a major global pharmaceutical partner.

 

Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a novel formulation of the partner's proprietary product with enhanced properties. The partner company will fully fund the formulation work with the potential for future license opportunities to follow.

 

Sarah Howell, Chief Executive Officer of Arecor, said: "Arecor continues to partner with the world's leading pharmaceutical companies, which is testament to our leadership position in the field of drug delivery and formulation innovation and further validates the potential of our proprietary technology platform, Arestat™ to enable enhanced formulations of partners' proprietary products which would otherwise be unachievable."

 

This announcement contains inside information for the purposes of the retained UK version of the

EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

 

 

For more information, please contact:

 

Arecor Therapeutics plc
www.arecor.com
Dr Sarah Howell, Chief Executive Officer
Tel: +44 (0) 1223 426060
Email:info@arecor.com
David Ellam, Chief Financial Officer
Tel: +44 (0) 1223 426060
Email:info@arecor.com
Singer Capital Markets Advisory LLP (NOMAD and Broker)
Phil Davies, Sam Butcher
Tel: +44 (0) 20 7496 3000
ICR Healthcare
Chris Gardner, David Daley, Lindsey Neville
Tel: +44 (0) 20 3709 5700
Email:arecor@icrhealthcare.com


 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
AGRKZGZFMKZGKZZ